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A B S T R A C T   
Background: The aim of this study was to evaluate the risk factors for hospitalizations of cases with positive and 
negative COVID-19 tests. 
Methods: In this case-control study, the case and control groups consisted of 292 COVID-19 patients and 296 non- 
COVID-19 patients. Patients who referred to a reference laboratory in Tehran (Iran) in March 2020 were selected 
and interviewed. The patients were contacted by telephone and data were recorded through a questionnaire. 
Results: The sample of this study consisted of 588 patients (349 [59%] females, 239 [41%] males) with a mean 
age of 42 ± 15. The results of this study showed that comorbidities like diabetes (OR = 7.42), hypertension (OR 
= 4.85), asthma and respiratory diseases (OR = 5.64) in addition to symptoms including fever (OR = 6.67), chills 
(OR = 11.2), anorexia (OR = 11.3), dyspnea (OR = 4.8), weakness and lethargy (OR = 5.7) were the most 
predictive variables for hospitalization of non-COVID-19 cases. Furthermore, demographical variables like male 
gender (OR = 3.71), high age (>50; OR = 3.12), BMI (>25; OR = 2.37), travel (OR = 2.79), comorbidities 
including diabetes (OR = 5.26), hypertension (OR = 3.7) and underlying immunosuppressant patients receiving 
corticosteroid therapy (OR = 3.62) in addition to symptoms like anorexia [OR = 2.55] and dyspnea (OR = 6.99) 
tend to increase the risk of hospital admission in COVID-19 patients, suggesting their predictive values for 
hospitalization of COVID-19 patients. 
Conclusion: Our results indicated that different factors tend to increase the odds of hospital admission in patients 
with positive and negative COVID-19 tests, suggesting their predictive values for hospitalization.   
1. Introduction 
1.1. Background 
The outbreak of COVID-19 disease in Wuhan (China) in late 2019 led 
to the World Health Organization (WHO) announcing a new pandemic 
in the world [1]. According to the WHO report until May 12, 2021, 
millions of people had been infected and died respectively duo to 
COVID-19 infections around the world [2]. In Iran, since the first two 
cases of COVID-19 were reported on February 19, 2020 [3]; until May 
12, 2021 [2], >2.5 million have been infected and >75 thousand people 
have died of COVID-19 disease. 
Abbreviations: ARD, Asthma and Respiratory Disease; ICU, Intensive Care Unit; KVSL, Keyvan Virology Specialty Laboratory; COT, Corticosteroid Therapy. 
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The clinical features of COVID-19 are varied, ranging from asymp-
tomatic states or mild upper respiratory tract infections to severe 
pneumonia with respiratory failure (acute respiratory distress syndrome 
[ARDS]) in the early stages or even death [4–5]. 
Major symptoms like fever, cough, dyspnea [4] and minor symptoms 
such as loss of taste and smell, gastrointestinal symptoms and cutaneous 
manifestations [6–9] are common clinical features of this disease. Booth 
et al. [10] in a meta-analysis study comprising of 76 studies across 14 
countries demonstrated that commonly reported variables including 
age > 75, male sex, severe obesity, active cancer, crucial measure (e.g., 
respiratory rate and SpO2) as patient characteristics contributing to an 
increased risk of severe COVID-19 infection . 
In a national cohort study of 88,747 cases tested for SARS-CoV-2, 
Loannou found that older age, high regional coronavirus disease 2019 
burden, higher Charlson Comorbidity Index score [11], fever, dyspnea, 
and abnormal results in many routine laboratory tests are significant risk 
factors for mortality, while other factors such as chronic obstructive 
pulmonary diseases, obesity, smoking and hypertension were not found 
to be linked to mortality [12]. A nationwide study reported that age, sex, 
and comorbidity are generally associated with severe COVID-19 [13]. 
As far as patient management is concerned, there is substantial in-
terest in examining risk factors associated with hospitalization, severe 
illness, and mortality in case series. Exploration of the epidemiology, 
details of the clinical characteristics (e.g., respiratory symptoms, etc.), 
laboratory and CT scan results, comorbidities, and clinical outcomes of 
patients are essential in this regard [14–16]. Some cases are discharged 
earlier, whereas others needed longer hospitalization; therefore, risk 
factor estimation and definitive outcomes need to be clarified. Since its 
outbreak, there have existed myriad uncertainties about COVID-19 
especially in different communities as well. Given most COVID-19 
studies have been performed on hospitalized patients rather than 
those receiving pre-hospital care, this study was aimed at evaluating the 
Fig. 1. Flow diagram of study and Analysis.  
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risk factors for hospitalizations among individuals with positive and 
negative COVID-19 tests. 
2. Materials and Methods: 
The front-line data of the present retrospective case-control study 
were obtained from Keyvan Virology Specialty Laboratory (KVSL) in 
Tehran, Iran. The KVSL was one of the main referral laboratories for 
screening suspected COVID-19 cases in Tehran. 
The inclusion criteria in this study were: 18 ≤ age ≤ 90, willingness 
to participate, reference to KVSL form 10 March to 23 March 2020, 
registration of correct information at the time of admission, and detec-
tion of COVID-19 virus through RT–PCR. Patients’ refusal to participate 
and failure to complete the interview were the exclusion criteria. The 
flow diagram of the study is presented in Fig. 1. A total of 6928 sus-
pected COVID-19 cases referred to KVSL form 10 March to 23 March 
2020. Based on the positive or negative RT-PCR of throat-swab speci-
mens, 866 confirmed COVID-19 patients and 6062 negative COVID-19 
cases were included and followed up. Finally, 292 and 296 cases who 
tested positive and negative for SARS-CoV-2 respectively were 
contacted. 
Study participants responded to a 40-item telephone-based interview 
checklist including demographic information, current diseases, clinical 
outcomes, signs and symptoms, designed by a team of specialists (i.e., 
epidemiologists, statisticians, pulmonologists and infectious disease 
specialists) who were treating or studying COVID-19 disease. The con-
tent and face validity of this checklist were approved with Content 
Validity Ratio (CVR) > 0.7. The time interval between the referrals of 
and phone calls to patients was minimum 10 days (Min = 10, Max = 16). 
2.1. Ethical considerations: 
In this study, the principle of information confidentiality was 
observed and participants would have willingly participated in this 
study. The research procedure was entirely consistent with the Human 
Ethics Committee of the Baqiyatallah University of Medical Sciences, 
and was implemented with an ethical number (IR.BMSU. 
REC.1399.044). 
2.2. Statistical analysis 
Categorical variables were compared by Chi-square (χ2) tests or 
Fisher’s Exact Test and presented as n (%), whereas continuous variables 
were compared using the Mann-Whitney U test and were reported as 
median (Inter Quartile Range). In this study, logistic regression (OR with 
95% confidence interval) was used to explore the risk factors related to 
COVID-19 and hospital admission. The SPSS software (version 18) and 
P-value<5% were used for statistical inferences and statistical signifi-
cances, respectively. 
3. Results 
The data were obtained from 292 laboratory-confirmed COVID-19 
patients and 296 non-COVID-19 patients referring to the KVSL in Teh-
ran, Iran, during the study period. The mean age was 44.42 years (SD: 
14.87; range: 19–90; IQR: 21), and 39.57 years (SD: 14.12; range: 
18–85; IQR: 19) for COVID-19 and non-COVID-19 cases, respectively. 
The most common comorbidities in this study were hypertension [n 
= 63,10.7%], diabetes [n = 53, 9.0%], asthma and respiratory diseases 
[n = 29, 4.9%], radiotherapy [n = 19, 3.2%], autoimmune diseases [n =
17, 2.9%], heart failure [n = 14, 2.8%], stomach problems [n = 14, 
2.8%], pregnancy [n = 9, 1.5%], coronary arteries [n = 8, 1.3%], cancer 
[n = 7, 1.1%], open-heart surgery [n = 5, 0.8%], chemotherapy [n = 3, 
0.5%] and history of dialysis [n = 2, 0.3%]. 
The demographics, baseline features, and symptoms of patients with 
and without COVID-19 are presented in Table 1, where diseases with a 
frequency of occurrence lower than 20 are not reported. 
The findings indicated that risk factors such as high age and BMI, 
smoking, diabetes, hypertension, and corticosteroid therapy can in-
crease the risk of COVID-19 (Table 1). As shown in Table 1, the findings 
revealed that signs and symptoms like fever, cough, and muscle pain/ 
body pain, headaches, dyspnea, chills, anorexia, weakness and lethargy 
were more frequent in COVID-19 patients compared with non-COVID-19 
patients. Based on the findings presented in Table 1, COVID-19 cases 
appear to be at increased risk for hospitalization, ICU hospitalization, 
and mortality. The risk factors for hospital admissions of COVID-19 and 
Table 1 











N (%) N (%) 
Gender (Male) 180(%62) 169(%57) 1.21 
(0.87–1.68) 
0.226 
Age (>50) 88(%30) 63(%21) 1.50 
(1.09–2.30) 
0.018 
BMI (>25) 191(%66) 148(%51) 1.87 
(1.34–2.61) 
<0.001 
Smoking (yes) 25(%9) 46(%16) 0.51 
(0.31–0.85) 
0.001 
Trips out of town(yes) 38(%13) 42(%14) 0.90 
(0.56–1.45) 
0.719 
Current disease     
Diabetes (yes) 40(%14) 13(%4) 3.45 
(1.81–6.61) 
<0.001 











18(6%) 6 (2%) 3.17 
(1.4–8.12) 
0.012 
Sign and symptom     
Fever (yes) 164(%56) 111(%38) 2.13 
(1.53–2.97) 
<0.001 
Cough (yes) 140(%48) 91(%31) 2.07 
(1.48–2.91) 
<0.001 
Sore throat (yes) 45(%15) 63(%21) 0.67 
(0.44–1.03) 
0.07 
Muscle and body pain 
(yes) 
112(%38) 63(%21) 2.30 
(1.59–3.31) 
<0.001 
Headaches (yes) 67(%23) 34(%12) 2.29 
(1.46–3.59) 
<0.001 
Diarrhea (yes) 20(%7) 14(%5) 1.48 
(0.73–2.99) 
0.293 
Nausea(yes) 37(%13) 22(%7) 1.81 
(1.04–3.15) 
0.039 
Dyspnea (yes) 77(%26) 44(%15) 2.05 
(1.35–3.10) 
<0.001 
Tachycardia (yes) 13(%5) 12(%4) 1.01 
(0.495–2.46) 
0.840 
Sweating (yes) 30(%10) 23(%8) 1.36 
(0.77–2.40) 
0.315 
Chills (yes) 101(%35) 48(%16) 2.73 
(1.85–4.04) 
<0.001 
Runny nose (yes) 29(%10) 43(%15) 0.65 
(0.39–1.07) 
0.109 





94(%32) 49(%17) 2.39 
(1.62–3.54) 
<0.001 
Outcomes     
Hospital admissions 48(16%) 14(5%) 3.96 
(2.13–7.36) 
<0.001 
ICU admissions 16 (6%) 5 (2%) 3.37 
(1.22–9.33) 
0.014 
Deaths 12 (4%) 2 (1%) 6.30 
(1.40–28.4) 
0.006 
OR: Odds Ratio, 95% CI: 95% Confidence Interval 
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non-COVID-19 patients are presented in Table 2 (i.e., signs and symp-
toms, demographic variables, and current disease status). The results 
revealed that comorbidities like diabetes, hypertension, asthma and 
respiratory diseases in addition to some symptoms such as fever, chills, 
dyspnea, anorexia, weakness and lethargy were the most predictive 
variables accounting for non-COVID-19 cases’ hospitalization. More-
over, demographical variables such as gender, age, BMI, travel, 
comorbidities including diabetes, hypertension and corticosteroid 
therapy and symptoms like anorexia and dyspnea were found to be the 
most predictive variables for hospitalization of COVID-19 patients. 
4. Discussion 
Numerous COVID-19 studies in Iran and other countries have been 
performed based on patients admitted to the hospital with moderate-to- 
severe coronavirus diseases, but the present study aimed to evaluate the 
risk factors affecting positive and negative COVID-19 test results. The 
aim of this retrospective case control study was to provide preliminary 
data on the risk of hospitalization among COVID-19 patients. 
In the current study, the main clinical symptoms of COVID-19 pa-
tients were fever (56%), cough (48%), muscle and body pain (38%), 
weakness and lethargy (32%), and dyspnea (26%), while minor symp-
toms included runny nose (10%), diarrhea (7%), and tachycardia (5%). 
These findings are more or less consistent with meta-analysis studies 
performed by Li et al. [17], Zhu et al. [18], Li et al [19], Qiu et al. [20], 
Pormohammad et al. [21] and Olumade et al. [22], indicating that in-
dividuals with clinical features linked to the disease should be moni-
tored closely. 
Our results also showed that signs and symptoms such as chills [OR 
= 2.73], weakness and lethargy (OR = 2.39], muscle and body pain [OR 
= 2.3], headaches [OR = 2.29], fever [OR = 2.13], cough [OR = 2.07] 
and dyspnea [OR = 2.05] were more frequent in COVID-19 patients 
compared with non-COVID-19 cases. Among the clinical symptoms 
recorded in our study, variables such as chills, fever, cough, fatigue or 
muscle pain, and headaches were not significant predictors of hospi-
talization, when the symptoms were separately considered in the model 
to evaluate the impact of the factors on the patients’ hospitalization. 
Therefore, regarding the risk of hospitalization, these symptoms could 
not be considered as general predictors. However, the present model 
identified dyspnea and anorexia as the most important symptoms 
associated with odds of hospitalization in COVID-19 patients, while 
anorexia was found to increase the odds of hospitalization in non- 
COVID-19 patients. 
Based on a systematic review and meta-analysis, the clinical mani-
festations such as fever [OR = 0.56] and shortness of breath or dyspnea 
[OR = 4.16] have attested to their association with the progression of 
the disease [23]. Another meta-analysis study reported that dyspnea 
[OR = 4.52], chest tightness [OR = 2.50], hemoptysis [OR = 2.00], 
expectoration [OR = 1.52] and fatigue [OR = 1.27] were significantly 
associated with increased risk of mortality in COVID-19 patients [24], 
indicating their values as independent predictors of death. Based on the 
data presented herein, older age [OR = 1.5] and obesity [OR = 1.87] 
were found to be more frequent in COVID-19 patients when compared 
with non-COVID-19 cases. This result was in line with previous studies. 
Yang et al. in a meta-analysis study [25] showed that obesity was linked 
to a higher risk of COVID-19 disease [OR = 1.39] and severity of COVID- 
19 (hospitalization rate [OR = 2.45], severe cases [OR = 3.74], need for 
intensive care unit admission [OR = 1.30], need for invasive mechanical 
ventilation [OR = 1.59] and mortality [ OR = 1.65]). 
We also found that a remarkable proportion of the patients admitted 
to hospital had a history of diabetes and/or BMI > 25 when all variables 
were separately considered in the model. Risk of hospitalization was 
higher among COVID-19 patients who had BMI>25 and diabetes. 
Xiang et al. [26] showed that the age of patients (age ≥ 60) is 
associated with in-hospital deaths [OR = 4.94]. Data from initial studies 
in China also indicated that case fatality ratio could be markedly 
elevated with age [27]. 
This study presented that the most commonly comorbidities of 
COVID-19 infections were diabetes [OR = 3.45], hypertension [OR =
2.81] and corticosteroid therapy (in immunosuppressed patients) [OR 
= 3.17]. Hypertension [OR = 2.29] and diabetes, etc. [OR = 2.47] have 
been reported to be independent risk factors linked to COVID-19 
severity by Wang et al. [28], suggesting their use for early medical 
management of COVID-19 disease. 
Table 2 
The risk factor for hospital admission in COVID-19 and non-COVID-19 patients.   
COVID-19 (Positive) COVID-19 (Negative) 
Demographic variables 
Hospitalized (yes) (n 
= 48) 
Hospitalized (no) (n =
244) 
OR 95% CI Hospitalized (yes) (n 
= 14) 
Hospitalized (no) (n =
282) 
OR 95% CI 
N (%) N (%) N (%) N (%) 
Gender (Male) 40 (83%) 140(57%) 3.71**(1.67–8.27) 5(36%) 164(58%) 0.4(0.13–1.22) 
Age (>50) 23(48%) 63(26%) 3.12**(1.65–5.89) 6(42%) 57(20%) 2.93(0.97–8.79) 
BMI (>25) 37(80%) 154(63%) 2.37*(1.09–5.15) 6(50%) 142(51%) 0.95(0.30–3.04) 
Smoking (yes) 3(6%) 22(9%) 0.67(0.19–2.34) 2(14%) 44(16%) 0.90(0.19–4.17) 
Trips out of town (yes) 12(25%) 26(10%) 2.79*(1.29–6.03) 4(29%) 38(13%) 2.5(0.76–8.60) 
Current disease       
Diabetes (yes) 17(35%) 23(9%) 5.26**(2.5–10.94) 3(21%) 10(3%) 7.42*(1.7–30.8) 
Hypertension (yes) 16(33%) 29(12%) 3.7*(1.81–7.57) 3(21%) 15(5%) 4.85* 
(1.22–19.26) 
Asthma and respiratory 
disease (yes) 
5(10%) 19(8%) 1.37 (0.49–3.88) 3(21%) 13(5%) 5.64* 
(1.40–22.17) 
Corticosteroid therapy (yes) 7(15%) 11(4%) 3.62* (1.32–9.87) 1 (7%) 5 (2%) 4.2 (0.46–39.2) 
Sign and symptom       
Fever (yes) 26(46%) 138(57%) 0.91(0.49–1.69) 11(79%) 100(35%) 6.67**(1.82–24.5) 
Cough (yes) 26(46%) 114(47%) 1.35(0.72–2.51) 4(29%) 87(31%) 0.90(0.27–2.94) 
Muscle or body pain (yes) 16(33%) 96(39%) 0.77(0.40–1.48) 6(43%) 57(20%) 2.96(0.99–8.87) 
Headache (yes) 10(21%) 57(23%) 0.86(0.40–1.84) 1(7%) 33(12%) 0.58(0.07–4.58) 
Nausea(yes) 38(79%) 10(21%) 2.11(0.95–4.73) 2(14%) 20(7%) 2.18(0.45–10.43) 
Dyspnea (yes) 30(62%) 47(19%) 6.99**(3.6–13.59) 6(43%) 39(13%) 4.8**(1.58–14.65) 
Chills (yes) 19(40%) 82(34%) 1.29(0.68–2.44) 9(64%) 39(14%) 11.2**(3.57–35.2) 
Anorexia (yes) 16(33%) 40(16%) 2.55**(1.28–5.08) 7(50%) 23(8%) 11.3**(3.63–34.2) 
Weakness and lethargy 28(58%) 20(42%) 1.64(0.86–3.09) 7(50%) 42(15%) 5.7**(1.96–17.13) 
ARD: Asthma and respiratory disease, COT: Corticosteroid Therapy, **: P-value < 0.01, *: P-value < 0.05 
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In the present study, the odds of hospitalization were found to be 
higher in males [OR = 3.71]. In a systematic review and meta-analysis, 
male gender [OR = 1.76] has been shown to have contributed to a 
higher risk of developing into critical or mortal conditions among 
COVID-19 patients [23]. This result can be justified by more risky be-
haviors in males and stronger immune responses of females [29]. 
It has been also reported that older age along with co-morbidities 
may be an important predictor of mortality resulting from COVID-19, 
SARS and MERS [30–32]. Therefore, in the initial screening; older pa-
tients who are immunocompromised should be considered as having a 
higher risk for developing moderate to severe form of the disease. 
The limitations of this study included the lack of some clinical and 
laboratory findings due to the design of study, access to KVSL infor-
mation only in the period from 10 March to 23 March 2020 and not 
using CT scan usage for increasing the accuracy of COVID-19 detection 
[33]. 
5. Conclusion 
Based on the results presented herein, having included Covid-19 
negative and positive cases, our data exhibited increasing odds of hos-
pital admissions associated with demographical variables like male 
gender, high age, BMI, travel, comorbidities including diabetes, hyper-
tension and underlying immunosuppressant patients receiving cortico-
steroid therapy in addition to symptoms like anorexia and dyspnea, 
indicating that motoring these indicators could have predictive values 
for such patients. 
The findings of this study may provide a framework in clinical 
practice. However, additional large samples are required to verify the 
findings. 
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